Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review

Review found no reports of nephrogenic systemic fibrosis (NSF) among 83,291 patients (20 non-comparative studies) exposed to newer gadolinium-based contrast agents (GBCAs). In 12 comparative studies (n=118,844), 37 cases developed with older vs 4 with newer GBCAs.

SPS commentary:

Authors conclude that although NSF occurrence after exposure to newer GBCAs is very rare, the relatively scarce data among patients with acute kidney injury and those with risk factors for chronic kidney disease limit conclusions about safety in these populations.

Annals of Internal Medicine